Sensei Biotherapeutics (SNSE) Price & Analysis

Compare

216 Followers

SNSE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.00 - $17.40

Previous CloseN/A

Volume8.76M

Average Volume (3M)26.71K

Market Cap

$9.88M

Enterprise Value-$21.20M

Total Cash (Recent Filing)$28.63M

Total Debt (Recent Filing)$2.56M

Price to Earnings (P/E)―

Beta1.69

Next Earnings

Nov 11, 2025

EPS Estimate

-3.73

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.91

Shares Outstanding1,261,290

10 Day Avg. Volume16,174

30 Day Avg. Volume26,709

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-2.15

Enterprise Value/Revenue-38.97

Enterprise Value/Gross Profit-207.82

Enterprise Value/Ebitda0.80

Forecast

1Y Price Target

$32.50

Price Target Upside305.24% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsFavorable clinical signals using solnerstotug in the Phase 1/2 could help establish the molecule as a real player in the checkpoint inhibitor (CKI) space.

Drug Safety And TolerabilitySolnerstotug appears to be safe and well tolerated as either a monotherapy or combination with cemiplimab.

Product DevelopmentSNS-101 could potentially be the first anti-VISTA monoclonal antibody approved as a therapeutic agent, with an anticipated launch in 2029.

Bears Say

Earnings EstimateDecreasing FY25 EPS estimate to ($0.94) from ($0.76).

Efficacy In Clinical TrialsNo complete or partial responses were observed in patients with 'cold' tumors, as expected, indicating limited efficacy in this group.

Financial PerformanceSensei announced 2Q25 financial results, posting EPS of ($3.91) compared to our estimate of ($0.31).

Sensei Biotherapeutics News

Sensei Biotherapeutics Inc trading resumes

09:40 EDT Sensei Biotherapeutics (SNSE) Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

14d ago

SNSE

Sensei Biotherapeutics Inc trading halted, volatility trading pause

09:35 EDT Sensei Biotherapeutics (SNSE) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate...

14d ago

SNSE

Sensei Biotherapeutics target adjusted to $30 from $5 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Sensei Biotherapeutics (SNSE) to $30 from $5 and keeps a...

24d ago

SNSE

Sensei Biotherapeutics reports Q2 EPS ($3.91) vs ($5.69) last year

“The second quarter was a key inflection point for Sensei, as we now transition from early response-focused readouts...

24d ago

SNSE

Sensei Biotherapeutics Reports Promising Q2 2025 Results

Sensei Biotherapeutics, Inc. ( ($SNSE) ) has released its Q2 earnings. Here is a breakdown of the information...

23d ago

SNSE

Sensei Biotherapeutics Regains Nasdaq Compliance

Sensei Biotherapeutics ( ($SNSE) ) has issued an update. On July 2, 2025, Sensei Biotherapeutics announced that it...

2M ago

SNSE

Sensei price target raised to $35 at Stephens to reflect 1-for-20 reverse split

Stephens raised the firm’s price target on Sensei Biotherapeutics (SNSE) to $35 from $4 and keeps an Overweight...

2M ago

SNSE

Sensei Biotherapeutics Inc trading halted, news pending

19:50 EDT Sensei Biotherapeutics (SNSE) Inc trading halted, news pending Published first on TheFly – the ultimate source...

2M ago

SNSE

Upcoming Stock Splits This Week (June 16 to June 20) – Stay Invested

These are the upcoming stock splits for the week of June 16 to June 20, based on TipRanks’ Stock...

2M ago

NCI

RGC

Sensei Biotherapeutics Announces Reverse Stock Split

Sensei Biotherapeutics ( ($SNSE) ) has shared an announcement. On June 12, 2025, Sensei Biotherapeutics announced a one-for-twenty...

3M ago

SNSE

Sensei announces 1-for-20 reverse stock split

Sensei Biotherapeutics (SNSE) announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding...

3M ago

SNSE

Sensei Biotherapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Sensei Biotherapeutics (SNSE) with a Buy rating and $5 price target Sensei is...

3M ago

SNSE

Sensei Biotherapeutics Approves Reverse Stock Split

The latest update is out from Sensei Biotherapeutics ( ($SNSE) ). On May 21, 2025, Sensei Biotherapeutics held...

3M ago

SNSE

Sensei Biotherapeutics Reports Promising Q1 2025 Results

Sensei Biotherapeutics, Inc. ( ($SNSE) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

SNSE

SNSE FAQ

What was Sensei Biotherapeutics’s price range in the past 12 months?

Sensei Biotherapeutics lowest stock price was $5.00 and its highest was $17.40 in the past 12 months.

What is Sensei Biotherapeutics’s market cap?

Sensei Biotherapeutics’s market cap is $9.88M.

When is Sensei Biotherapeutics’s upcoming earnings report date?

Sensei Biotherapeutics’s upcoming earnings report date is Nov 11, 2025 which is in 74 days.

How were Sensei Biotherapeutics’s earnings last quarter?

Sensei Biotherapeutics released its earnings results on Aug 05, 2025. The company reported -$3.91 earnings per share for the quarter, beating the consensus estimate of -$5.6 by $1.69.

Is Sensei Biotherapeutics overvalued?

According to Wall Street analysts Sensei Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sensei Biotherapeutics pay dividends?

Sensei Biotherapeutics does not currently pay dividends.

What is Sensei Biotherapeutics’s EPS estimate?

Sensei Biotherapeutics’s EPS estimate is -3.73.

How many shares outstanding does Sensei Biotherapeutics have?

Sensei Biotherapeutics has 1,261,290 shares outstanding.

What happened to Sensei Biotherapeutics’s price movement after its last earnings report?

Sensei Biotherapeutics reported an EPS of -$3.91 in its last earnings report, beating expectations of -$5.6. Following the earnings report the stock price went down -4.74%.

Which hedge fund is a major shareholder of Sensei Biotherapeutics?

Currently, no hedge funds are holding shares in SNSE

Sensei Biotherapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-64.18%

Trailing 12-Months

Asset Growth

-42.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immunotherapies for the treatment of cancer. The company operates in the biotechnology and pharmaceutical sectors, leveraging its innovative ImmunoPhage™ platform to develop a pipeline of novel therapies aimed at modulating the immune system to recognize and destroy cancer cells. Sensei's core product candidates are designed to target various types of cancer, offering potential new treatment options for patients with unmet medical needs.

Sensei Biotherapeutics (SNSE) Earnings & Revenues

Historic Earnings Reports

SNSE Stock 12 Month Forecast

Average Price Target

$32.50

▲(305.24% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","36":"$36","12.75":"$12.75","20.5":"$20.5","28.25":"$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.75,20.5,28.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.32,12.218461538461538,14.116923076923078,16.015384615384615,17.913846153846155,19.81230769230769,21.71076923076923,23.60923076923077,25.50769230769231,27.406153846153845,29.304615384615385,31.203076923076924,33.10153846153846,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.32,12.026153846153846,13.732307692307693,15.438461538461539,17.144615384615385,18.85076923076923,20.556923076923077,22.263076923076923,23.96923076923077,25.675384615384615,27.38153846153846,29.087692307692308,30.793846153846154,{"y":32.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.32,11.833846153846155,13.347692307692308,14.861538461538462,16.375384615384615,17.88923076923077,19.403076923076924,20.916923076923077,22.43076923076923,23.944615384615386,25.45846153846154,26.97230769230769,28.486153846153847,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.73,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.46,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.79,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.99,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >